Next Generation Clinical Research Receives Dane County Small Business Award

Madison, Wisconsin-June 19, 2009- Next Generation Clinical Research is proud to announce it has been named one of this year’s recipients of the Dane County Small Business Award. This prestigious award recognizes small businesses in Dane County who are making strong contributions to our communities and economy.

“It is a great honor to be selected as one of the award recipients this year. This is especially exciting as we celebrate our tenth anniversary.” commented Laura L. Douglass, President & CEO of Next Generation.

Next Generation provides services to small and mid-sized pharmaceutical and biotech companies in the development of new drugs. The company manages clinical trials throughout the US and Canada while providing medical safety oversight and data management services. Douglass credits “employee expertise and adaptability” for company’s continued success in a fast paced and highly regulated industry. Next Generation’s work has supported the approval of new medications in areas of neurological disorders and kidney disease. Douglass relayed “It’s exciting to have a role in finding new cures and impacting people’s lives”.

Next Generation was also recognized for their community contributions as the company sponsors high school scholarships and contributes to numerous local charity and volunteer organizations. Next Generation received the award at a breakfast ceremony emceed by Jody Glynn Patrick of InBusiness Magazine with comments by Dane County Executive, Kathleen Falk. The award is coordinated by the University of Wisconsin Small Business Development Center with judges from different industry sectors each year. Award sponsors for 2009 included Centro Hispano, Chase, In Business Magazine, Madison Gas & Electric, Mid-West Family Broadcasting, Urban League of Greater Madison, UW-Madison Small Business Development Center, Wisconsin Business Development Finance Corporation.

ABOUT NEXT GENERATION – Next Generation is a Contract Research Organization (CRO) focused on providing clinical trial management services to small and mid-sized pharmaceutical and biotech organizations. The company was founded in 1999 and conducts novel, complex clinical trial projects throughout the United States and Canada.

Christine Wood-Tank
Next Generation Clinical Research
Phone: 608-835-5811

NovaScan, LLC today announced that it has raised $285,000 for improved cancer detection technology.

Milwaukee, WI – NovaScan, LLC today announced that it has raised $285,000 in equity funding from Angel investors with another $100,000 available to the Company through grants and loans. NovaScan, located at the Cozzens-Cudahy Research Center in Milwaukee, is developing proprietary technology to improve cancer detection.

A co-winner of the first annual Governor’s Business Plan contest in 2004, NovaScan said that the money is being used to finance the production and testing of a prototype breast cancer imaging device. This device, which identifies tissue types inside the breast based on their electrical properties, is designed to augment X-ray mammography.

According to co-founder and CEO Larry Wells, the Company has conducted in vitro measurements on breast tissue acquired from surgical biopsies, lumpectomies and mastectomies. “This has allowed us to catalog the different electrical properties of breast tissues and tumors and the next step is in vivo scanning of patients who are scheduled for a biopsy,” Wells said. “This will help us evaluate the ability of our technology to distinguish malignant from benign tumors and lay the ground work for broader clinical trials and regulatory testing,” added Dr. William Gregory, founder and chief scientist. NovaScan expects to begin clinical feasibility testing at an area hospital in September and it will include up to 50 patients.

According to the Company, with about 213,000 new breast cancer cases each year in the U.S. and 41,000 deaths, there is an enormous need for improved technology to diagnose cancer earlier. If successful, NovaScan hopes to eliminate the requirement for multiple diagnostic procedures to determine the presence of cancer.

Eventually, the Company hopes to reduce or negate the need for invasive procedures such as biopsies. “Our technology if used at the breast cancer screening stage could save the health care system millions of dollars per year and it has the potential to be expanded for use in the detection of cancers in other parts of the body,” said Wells.

Continue reading "NovaScan, LLC today announced that it has raised $285,000 for improved cancer detection technology." »

Affinity Introduces New Service

Affinity Introduces New Service that Improves Return on Investment on Technology Investment Dollars

Milwaukee, WI – March 31, 2006 – Affinity, Inc. announced today its launch of their Technology Adoption Solution. The offering provides a process driven approach to managing and implementing necessary changes, in order to increase the use of new technology. The results are greater returns on technology investments and enhanced business performance.

Adoption has been identified, as one of the largest issues in realizing optimal benefits in technology investments. The Affinity solution enables organizations to affect the rate at which users adopt new systems. Adoption also identifies issues related to training, systems and process, providing resolve recommendations and a method to measure success.

Continue reading "Affinity Introduces New Service" »

Neurognostics signs a strategic partnership with Medical Numerics

Neurognostics signs a strategic partnership with Medical Numerics

Milwaukee, WI, March 29, 2006 – Neurognostics, Inc., a Milwaukee-based company specializing in functional Magnetic Resonance Imaging (fMRI) products and services, has signed a strategic partnership agreement with Medical Numerics, Inc., a software development company specializing in medical image visualization and analysis.

Working to provide the clinical community with the most comprehensive functional MR Imaging fMRI tools and applications, Neurognostics and Medical Numerics today announced a strategic alliance to deliver a new line of products to enhance fMRI’s utility in a clinical setting. The new product line will be based on Medical Numerics’ proprietary fMRI tool set, and Neurognostics’ MindState fDPD fMRI application software.

“We are thrilled about the opportunity to work with Medical Numerics,” said Neurognostics’ CEO, Douglas M. Tucker, Ph.D., M.B.A. “Both of our goals include advancing fMRI technology into clinical practice. It made sense for us to collaborate on our efforts to develop clinically useful fMRI tools and make them available to the clinical community. We explored a range of options to deliver fMRI tools into the hands of clinicians worldwide and concluded that Medical Numerics’ fMRI software solutions were by far the best. By partnering with Medical Numerics, we have the opportunity to add value by integrating our fMRI applications knowledge and expertise into one of the leading image visualization and analysis applications, and ultimately, leverage our expertise into the marketplace through Medical Numerics’ software applications and its scanner OEM relationships.”

“I am very excited about working with Neurognostics,” said Bob Steagall, Chief Operating Officer of Medical Numerics. “In combining their domain expertise in fMRI for detecting and staging central nervous system disorders with our expertise in software engineering and fMRI for neurosurgical planning, we will be able to offer our scanner OEM partners a set of fMRI applications of unmatched clinical utility. Our OEM partners will in turn be able to provide leading-edge clinical fMRI tools of the highest quality to their customers, ultimately benefiting the patient.”

Continue reading "Neurognostics signs a strategic partnership with Medical Numerics" »

Neurognostics Elects New Board Member

Neurognostics Elects New Board Member

Milwaukee, WI, August 29, 2005 – Neurognostics, Inc., the leader in functional Magnetic Resonance Imaging (fMRI) products and services, is pleased to announce the election of Milton Silva-Craig to its Board of Directors. Mr. Silva-Craig will begin his service as a Board Director as of the next regularly scheduled Board meeting.

Mr. Silva-Craig is the President and Chief Operating Officer of Emageon Inc., (NASDAQ: EMAG). Mr. Silva-Craig joined Emageon in March, 2001 as its COO. Emageon provides enterprise-based, medical image management software and services. Prior to joining Emageon, Mr. Silva-Craig held key leadership positions in marketing and sales, business development, product development and operations during his eight years at General Electric Medical Systems, a leading provider of medical diagnostic imaging equipment and information technologies. Mr. Silva-Craig holds a BA in International Relations, an MBA in International Business and Marketing, and a JD in Corporate Law from the University of Wisconsin – Madison.

"Milton has a tremendous track record in the field of medical imaging, both in a multi-national setting and most recently with a successful start-up organization. His experience, knowledge and demonstrated success in the field are great assets. I'm excited at the prospect of working with him and certain that he will be able to make significant contributions to the company’s success," said Jeff Rusinow, Neurognostics’ Board Chairman.

Founded in 2003, Neurognostics strives to enhance the quality of life for millions of patients suffering from disorders of the central nervous system (CNS) by developing, validating, and implementing applications that release the clinical power of fMRI. fMRI is a powerful imaging technique that extends the capability of Magnetic Resonance (MR) imaging by providing information about the functioning of imaged tissue. The Company strives to develop applications that will become the standard technique to assess and manage patients suffering from a variety of CNS disorders.

Continue reading "Neurognostics Elects New Board Member" »

WI Budget: Biomedical Technology Alliance to Administer Southeastern WI Research Initiative

Sen. Kanavas: Seeks Funds for Biomedical Technology Alliance:

High tech research initiative to be centered in Southeastern Wisconsin

(Madison) May 26, 2005… On a vote of 15-1 last evening, the Legislature’s Joint Committee on Finance, approved a proposal offered by Senator Ted Kanavas (R-Brookfield) to provide funding for a high-tech research initiative in Southeastern Wisconsin.

“The benefits are limitless. This initiative will provide a tremendous opportunity to create high-tech, high-paying jobs for our state. Private industry and local academic institutions will be able to partner together and take advantage of the wealth of knowledge and know how in Southeastern Wisconsin,” Kanavas stated.

The initiative will be administered by the Biomedical Technology Alliance (BTA). The BTA will build bridges, joining academic institutions such as UW-Milwaukee, the Medical College of Wisconsin, Marquette University, the Milwaukee School of Engineering, and UW-Parkside with local industry to increase biomedical research and development capacity in Southeastern Wisconsin.

Continue reading "WI Budget: Biomedical Technology Alliance to Administer Southeastern WI Research Initiative" »

Harold D. Gehrke, JD Joins Gehrke & Associates, S.C.

Gehrke & Associates, S.C. is pleased to announce that Harold D. Gehrke, JD has been named of counsel to the firm. His practice focuses on municipal law, including land use, zoning and development, as well as local government relations. He will be augmenting Gehrke & Associates, S.C. growing Wisconsin-based business practice.

“While our intellectual property focus tends to orient our law firm to federal and international law, many of our clients have communicated their need for legal assistance with local matters. This is especially true when they are starting their business or when they are expanding their business.” says Lisa M. Gehrke, JD, owner of Gehrke & Associates, S.C.. “As a small-business owner, I know that many times the actions of local government can have a significant impact on the bottom line of a business.”

Continue reading "Harold D. Gehrke, JD Joins Gehrke & Associates, S.C." »